

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 16003891		Fecha Prioridad: 07 de mayo de 2014		
CRITERIOS PARA LA BÚSQUEDA				
Palabras clave utilizadas		monoclonal AND antibody AND GM-CSF AND composition AND excipients AND stab* AND buffe* AND aminoac* AND surfactant AND antioxid* AND *toni* AND chela*		
		GM-CSF AND composition AND excipients AND (stab* OR buffe* OR aminoac* OR surfactant OR antioxid* OR *toni* OR chela*)		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 47/10 OR A61K 38/00 OR A61K 39/00 OR A61K 47/18 OR A61K 9/08 OR A61K 47/26		
DOCUMENTOS CONSIDERADOS RELEVANTES				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	Ninguna	---	---	---
ISA/IPEA (DE) Espacenet	EP1947178	23/07/2008	1 - 23	Y
	US2001014326	16/08/2001	1 - 23	Y
	WO2009038760	26/03/2009	1 - 23	Y
USPTO	US8017748	13/09/2011	1 - 23	Y
	WO2009038760	26/03/2009	1 - 23	Y
	US20030138417	24/07/2003	1 - 23	Y
Patbase	WO0212294	14/02/2002	---	A
	WO11106297	07/02/2013	---	A
	WO11139985	10/02/2011	---	A
Google Patents	---	---	---	---
Orbit	CA2946230	04/05/2014	1 - 23	A
	WO9412526	23/11/1992	1 - 23	A
	WO2014068029	31/10/2013	1 - 23	A
	CA2889307	30/10/2013	1 - 23	A
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	https://www.ncbi.nlm.nih.gov/pubmed/21406226 “Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development” European Journal of Pharmaceutics and Biopharmaceutics 78 (2011) 208–212.
---	---

Fecha del reporte de búsqueda:	20 de junio de 2018
---------------------------------------	---------------------

<
>
↻

Es seguro

https://www.google.com.co/search?tbm=pts&source=hp&ei=HF8qW7X-PPHK5gK6143ACg&q=M...

Monoclonal AND antibody AND GM-CSF AND composition AND excipie

Todo

Noticias

Imágenes

Videos

Más

Preferencias

Herramientas

Cerca de 0 resultados (0,47 segundos)

Quizás quisiste decir: [Monoclonal AND antibody AND GM-CSF AND composition AND excipients AND stab* AND *buffer** AND *aminoacyl** AND surfactant AND antioxidant* AND *toni* AND chela*](#)

No se ha encontrado ningún resultado de patente para la búsqueda "**Monoclonal AND antibody AND GM-CSF AND composition AND excipients AND stab* AND *buffer** AND *aminoac** AND surfactant AND antioxidant* AND *toni* AND chela***".

[vivo penetration mechanics: Topics by Science.gov](#)
<https://www.science.gov/topicpages/v/vivo+penetration+mechanics.html>
They differ by their **structure**, presence in the skin, and mode of application in Sucrose esters as biocompatible **surfactants** for penetration enhancement: An We have generated three **monoclonal** cell-penetrating **antibodies** (CPABs) and upregulation of proinflammatory cytokines, IL8 and **GM-CSF** in intestinal ...

[Resultados de Monoclonal AND antibody AND GM-CSF ... »](#)

#	Search query	Results	Options
4	Monoclonal AND antibody AND GM-CSF AND composition AND excipients AND stab* AND <i>buffer</i> * AND <i>aminoac</i> * AND surfactant AND antioxidant* AND *toni* AND chela*	6	View Browse Hits Optimise more...
3	Monoclonal AND antibody AND GM-CSF AND composition AND excipients AND stab*	55	View Browse Hits Optimise more...
2	Monoclonal AND antibody AND GM-CSF AND composition AND excipients AND <2014	0	
1	Monoclonal AND antibody AND GM-CSF AND composition AND excipients	72	View Browse Hits Optimise more...

20734 results for (GM-CSF AND composition AND excipients AND (stab+ OR buffe+ OR aminoac+ OR surfactant OR antioxi+ OR +toni+ OR chela+))						
Select Save strategy # Title Publication number 1st App. date Applicant/Assignee Relevanc Litigation						
25	Liquid formulation comprising gm-csf neutralizing compound The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators , wherein the composition is stable . The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders.	CA2946230	2015-05-04	TAKEDA*	100 %	
26	Purification of fusion proteins comprising gm-csf and il-3. A process for purifying a fusion protein comprising GM-CSF and IL-3 is disclosed.	WO9412526	1992-11-23	IMMUNEX*	100 %	
27	Lyophilized formulation comprising gm-csf neutralizing compound The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF , a lyoprotectant and an amino acid and/or a buffer . The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilisation, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.	WO2014068029	2013-10-31	AMGEN RESEARCH MUNICH* TAKEDA*	100 %	
28	Liquid formulation comprising gm-csf neutralizing compound	CA2889307	2013-10-30	AMGEN RESEARCH MUNICH*	100 %	